Tirbanibulin (Klisyri)
Overview
Tirbanibulin is a small molecule synthetic peptide mimetic that inhibits tubulin polymerization and disrupts Src kinase signaling pathways. It is applied topically as a 1% ointment to treat actinic keratosis, a precancerous skin condition caused by chronic sun exposure. The dual mechanism targets both the cytoskeleton and oncogenic signaling in hyperproliferative keratinocytes. Its localized application minimizes systemic exposure while achieving targeted antiproliferative effects.
Key Research Findings
Two phase III trials (KX01-AK-003 and KX01-AK-004) demonstrated superior complete clearance of actinic keratosis lesions compared to vehicle, with a five-day treatment course (Journal of the American Academy of Dermatology, 2021). The FDA approved tirbanibulin in December 2020 for topical treatment of actinic keratosis on the face or scalp. Post-marketing use has confirmed favorable tolerability with primarily local skin reactions.
Topical
FDA Approved
Interested in Tirbanibulin (Klisyri)?
Find a verified provider experienced with Tirbanibulin (Klisyri) protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Tirbanibulin (Klisyri) ProviderRelated Peptides
Carfilzomib (Kyprolis)
FDA ApprovedA tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds the chymotrypsin-like (beta5) subunit of the 20S proteasome. By blocking proteasomal degradation of ubiquitinated proteins, carfilzomib causes accumulation of misfolded proteins, endoplasmic reticulum stress, and activation of the unfolded protein response, leading to apoptosis preferentially in malignant plasma cells. Its irreversible binding confers greater proteasome inhibition than bortezomib.
Bortezomib (Velcade)
FDA ApprovedA modified dipeptidyl boronic acid that reversibly inhibits the chymotrypsin-like activity of the 26S proteasome. Bortezomib disrupts the ubiquitin-proteasome pathway, stabilizing pro-apoptotic factors and inhibiting NF-kB activation, which is constitutively active in many hematologic malignancies. It was the first proteasome inhibitor approved for cancer treatment and fundamentally changed the treatment landscape of multiple myeloma.
Lutetium-177 dotatate (Lutathera)
FDA ApprovedA radiolabeled somatostatin analog consisting of the peptide DOTA-Tyr3-octreotate chelated to the beta-emitting radioisotope lutetium-177. Lutathera binds with high affinity to somatostatin receptor subtype 2 (SSTR2), which is overexpressed on neuroendocrine tumor cells, delivering targeted radiation therapy directly to tumor cells while sparing surrounding normal tissue. This peptide receptor radionuclide therapy (PRRT) approach combines receptor-targeted delivery with cytotoxic radiation.
Leuprolide (Lupron) - Oncology
FDA ApprovedA GnRH agonist used in oncology for androgen deprivation therapy (ADT) in prostate cancer and hormone suppression in premenopausal breast cancer. Chronic administration produces sustained downregulation of pituitary GnRH receptors, achieving medical castration with testosterone levels below 50 ng/dL. The initial testosterone flare can be mitigated by co-administration of an antiandrogen. Depot formulations provide sustained release for up to 6 months.